Everything drug pricing and policy, every day
And a German-government-backed MFN study exposes a contradiction at the heart of the U.S. approach to international prices
Plus links on the politics of MFN deals and the contribution of 340B to health-spending growth
And why CVS’ plan to split is unlikely to mollify critics
Plus CVS unveils plan to spin off its retail pharmacy business amidst policy pressures
And Alnylam faces down a 340B earthquake
And Medicare will pay $6 billion in illegal duplicate 340B discounts next year, IQVIA estimates
Plus thoughts on TrumpRx, GLP-1s in Medicare, and a boatload of links
My new publication with Sean Sullivan and Aidan Sullivan indicates 11 million American seniors could be eligible for CMS’ obesity-med pilot
Plus thoughts on what the lack of 340B dialogue around key midterm battles says about policymaking in the new Congress
